Analyst Price Target is $18.83
▲ +211.29% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Zura Bio in the last 3 months. The average price target is $18.83, with a high forecast of $26.00 and a low forecast of $10.00. The average price target represents a 211.29% upside from the last price of $6.05.
Current Consensus is
Buy
The current consensus among 6 investment analysts is to buy stock in Zura Bio. This Buy consensus rating has held steady for over two years.
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Read More